# A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

> **NCT04245839** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Celgene** · enrollment: 276 (estimated)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** JCAR017

## Key facts

- **NCT ID:** NCT04245839
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-14
- **Primary completion:** 2031-09-30
- **Final completion:** 2031-09-30
- **Target enrollment:** 276 (ESTIMATED)
- **Last updated:** 2025-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04245839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04245839, "A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT04245839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*